Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683475 · ClinicalTrials.gov registry record · Phase 2
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT00683475 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 138 participants.
The verdict
NCT00683475, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).
Interventions
- DRUG Prednisone
- DRUG Mitoxantrone
- BIOLOGICAL IMC-A12
- BIOLOGICAL IMC-1121B (ramucirumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2008-08 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00683475
The ClinicalTrials.gov registry entry for NCT00683475 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prednisone is the first listed.
NCT00683475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00683475 about?
NCT00683475 is a clinical study titled "A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer". The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).
What is the current status of trial NCT00683475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2008-08. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00683475?
The interventions under investigation include: Prednisone (DRUG), Mitoxantrone (DRUG), IMC-A12 (BIOLOGICAL), IMC-1121B (ramucirumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00683475?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.